Teniposide (VM-26) as a single drug treatment for patients with extensive small cell lung carcinoma: A Phase II Study of the Southwest Oncology Group

Petre N. Grozea, John J. Crowley, Vikki A. Canfield, Laura Kingsbury, S. William Ross, German S. Beltran, Leslie Rodgers Laufman, Geoffrey R. Weiss, Robert B Livingston

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

BACKGROUND. Teniposide (VM-26) was reported to have activity in small cell lung carcinoma (SCLC). The authors performed a Phase II study of teniposide as a treatment for patients with previously untreated extensive SCLC. METHODS. The study was open to patients with a histologic or cytologic diagnosis of extensive SCLC who had not received prior radiation or chemotherapy. Patients with hematologic values below normal were considered eligible if the impaired bone marrow function was directly attributable to disease involvement. Treatment consisted of teniposide 60 mg/m2 given intravenously (i.v.) on Days 1-5 every 3 weeks. RESULTS. This study opened on September 15, 1988, closed permanently on November 15, 1990, and accrued 45 patients identified at 19 academic, military, and Community Clinical Oncology Program institutions affiliated with the Southwest Oncology Group. Of the 45 registered patients, 41 were eligible. Twenty eight (68%) were males and 18 (82%) were females; the median age was 64 years (minimum, 46 years; maximum, 83 years). Twenty-four patients (59%) had a performance status (PS) on the Zubrod scale of 0-1 and 17 cases (41%) had a PS of 2. Of the 41 eligible patients, 10 had confirmed partial responses (24%) (95% confidence interval, 12-40%). The median survival was 7 months. The significant toxicities noted were Grade 4 leukopenia and/or granulocytopenia, experienced by 15 patients; 1 of these patients also had Grade 4 hyponatremia. One patient died of a respiratory infection. CONCLUSIONS. When administered according to the dosage and schedule selected for this study (60 mg/m2 i.v. on Days 1-5 every 3 weeks), teniposide as a single agent had modest activity in extensive small cell lung carcinoma. The toxicities observed in this study were acceptable.

Original languageEnglish (US)
Pages (from-to)1029-1033
Number of pages5
JournalCancer
Volume80
Issue number6
DOIs
StatePublished - Sep 15 1997
Externally publishedYes

Fingerprint

Teniposide
Small Cell Lung Carcinoma
Pharmaceutical Preparations
Therapeutics
Agranulocytosis
Medical Oncology
Hyponatremia
Leukopenia
Respiratory Tract Infections
Appointments and Schedules
Reference Values
Bone Marrow

Keywords

  • Cooperative group
  • Extensive small ceil lung carcinoma
  • Phase II study
  • Teniposide

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Teniposide (VM-26) as a single drug treatment for patients with extensive small cell lung carcinoma : A Phase II Study of the Southwest Oncology Group. / Grozea, Petre N.; Crowley, John J.; Canfield, Vikki A.; Kingsbury, Laura; Ross, S. William; Beltran, German S.; Laufman, Leslie Rodgers; Weiss, Geoffrey R.; Livingston, Robert B.

In: Cancer, Vol. 80, No. 6, 15.09.1997, p. 1029-1033.

Research output: Contribution to journalArticle

Grozea, Petre N. ; Crowley, John J. ; Canfield, Vikki A. ; Kingsbury, Laura ; Ross, S. William ; Beltran, German S. ; Laufman, Leslie Rodgers ; Weiss, Geoffrey R. ; Livingston, Robert B. / Teniposide (VM-26) as a single drug treatment for patients with extensive small cell lung carcinoma : A Phase II Study of the Southwest Oncology Group. In: Cancer. 1997 ; Vol. 80, No. 6. pp. 1029-1033.
@article{c05780d7425a42f0aec08425f078c5c9,
title = "Teniposide (VM-26) as a single drug treatment for patients with extensive small cell lung carcinoma: A Phase II Study of the Southwest Oncology Group",
abstract = "BACKGROUND. Teniposide (VM-26) was reported to have activity in small cell lung carcinoma (SCLC). The authors performed a Phase II study of teniposide as a treatment for patients with previously untreated extensive SCLC. METHODS. The study was open to patients with a histologic or cytologic diagnosis of extensive SCLC who had not received prior radiation or chemotherapy. Patients with hematologic values below normal were considered eligible if the impaired bone marrow function was directly attributable to disease involvement. Treatment consisted of teniposide 60 mg/m2 given intravenously (i.v.) on Days 1-5 every 3 weeks. RESULTS. This study opened on September 15, 1988, closed permanently on November 15, 1990, and accrued 45 patients identified at 19 academic, military, and Community Clinical Oncology Program institutions affiliated with the Southwest Oncology Group. Of the 45 registered patients, 41 were eligible. Twenty eight (68{\%}) were males and 18 (82{\%}) were females; the median age was 64 years (minimum, 46 years; maximum, 83 years). Twenty-four patients (59{\%}) had a performance status (PS) on the Zubrod scale of 0-1 and 17 cases (41{\%}) had a PS of 2. Of the 41 eligible patients, 10 had confirmed partial responses (24{\%}) (95{\%} confidence interval, 12-40{\%}). The median survival was 7 months. The significant toxicities noted were Grade 4 leukopenia and/or granulocytopenia, experienced by 15 patients; 1 of these patients also had Grade 4 hyponatremia. One patient died of a respiratory infection. CONCLUSIONS. When administered according to the dosage and schedule selected for this study (60 mg/m2 i.v. on Days 1-5 every 3 weeks), teniposide as a single agent had modest activity in extensive small cell lung carcinoma. The toxicities observed in this study were acceptable.",
keywords = "Cooperative group, Extensive small ceil lung carcinoma, Phase II study, Teniposide",
author = "Grozea, {Petre N.} and Crowley, {John J.} and Canfield, {Vikki A.} and Laura Kingsbury and Ross, {S. William} and Beltran, {German S.} and Laufman, {Leslie Rodgers} and Weiss, {Geoffrey R.} and Livingston, {Robert B}",
year = "1997",
month = "9",
day = "15",
doi = "10.1002/(SICI)1097-0142(19970915)80:6<1029::AID-CNCR4>3.0.CO;2-4",
language = "English (US)",
volume = "80",
pages = "1029--1033",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "6",

}

TY - JOUR

T1 - Teniposide (VM-26) as a single drug treatment for patients with extensive small cell lung carcinoma

T2 - A Phase II Study of the Southwest Oncology Group

AU - Grozea, Petre N.

AU - Crowley, John J.

AU - Canfield, Vikki A.

AU - Kingsbury, Laura

AU - Ross, S. William

AU - Beltran, German S.

AU - Laufman, Leslie Rodgers

AU - Weiss, Geoffrey R.

AU - Livingston, Robert B

PY - 1997/9/15

Y1 - 1997/9/15

N2 - BACKGROUND. Teniposide (VM-26) was reported to have activity in small cell lung carcinoma (SCLC). The authors performed a Phase II study of teniposide as a treatment for patients with previously untreated extensive SCLC. METHODS. The study was open to patients with a histologic or cytologic diagnosis of extensive SCLC who had not received prior radiation or chemotherapy. Patients with hematologic values below normal were considered eligible if the impaired bone marrow function was directly attributable to disease involvement. Treatment consisted of teniposide 60 mg/m2 given intravenously (i.v.) on Days 1-5 every 3 weeks. RESULTS. This study opened on September 15, 1988, closed permanently on November 15, 1990, and accrued 45 patients identified at 19 academic, military, and Community Clinical Oncology Program institutions affiliated with the Southwest Oncology Group. Of the 45 registered patients, 41 were eligible. Twenty eight (68%) were males and 18 (82%) were females; the median age was 64 years (minimum, 46 years; maximum, 83 years). Twenty-four patients (59%) had a performance status (PS) on the Zubrod scale of 0-1 and 17 cases (41%) had a PS of 2. Of the 41 eligible patients, 10 had confirmed partial responses (24%) (95% confidence interval, 12-40%). The median survival was 7 months. The significant toxicities noted were Grade 4 leukopenia and/or granulocytopenia, experienced by 15 patients; 1 of these patients also had Grade 4 hyponatremia. One patient died of a respiratory infection. CONCLUSIONS. When administered according to the dosage and schedule selected for this study (60 mg/m2 i.v. on Days 1-5 every 3 weeks), teniposide as a single agent had modest activity in extensive small cell lung carcinoma. The toxicities observed in this study were acceptable.

AB - BACKGROUND. Teniposide (VM-26) was reported to have activity in small cell lung carcinoma (SCLC). The authors performed a Phase II study of teniposide as a treatment for patients with previously untreated extensive SCLC. METHODS. The study was open to patients with a histologic or cytologic diagnosis of extensive SCLC who had not received prior radiation or chemotherapy. Patients with hematologic values below normal were considered eligible if the impaired bone marrow function was directly attributable to disease involvement. Treatment consisted of teniposide 60 mg/m2 given intravenously (i.v.) on Days 1-5 every 3 weeks. RESULTS. This study opened on September 15, 1988, closed permanently on November 15, 1990, and accrued 45 patients identified at 19 academic, military, and Community Clinical Oncology Program institutions affiliated with the Southwest Oncology Group. Of the 45 registered patients, 41 were eligible. Twenty eight (68%) were males and 18 (82%) were females; the median age was 64 years (minimum, 46 years; maximum, 83 years). Twenty-four patients (59%) had a performance status (PS) on the Zubrod scale of 0-1 and 17 cases (41%) had a PS of 2. Of the 41 eligible patients, 10 had confirmed partial responses (24%) (95% confidence interval, 12-40%). The median survival was 7 months. The significant toxicities noted were Grade 4 leukopenia and/or granulocytopenia, experienced by 15 patients; 1 of these patients also had Grade 4 hyponatremia. One patient died of a respiratory infection. CONCLUSIONS. When administered according to the dosage and schedule selected for this study (60 mg/m2 i.v. on Days 1-5 every 3 weeks), teniposide as a single agent had modest activity in extensive small cell lung carcinoma. The toxicities observed in this study were acceptable.

KW - Cooperative group

KW - Extensive small ceil lung carcinoma

KW - Phase II study

KW - Teniposide

UR - http://www.scopus.com/inward/record.url?scp=0030772116&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030772116&partnerID=8YFLogxK

U2 - 10.1002/(SICI)1097-0142(19970915)80:6<1029::AID-CNCR4>3.0.CO;2-4

DO - 10.1002/(SICI)1097-0142(19970915)80:6<1029::AID-CNCR4>3.0.CO;2-4

M3 - Article

C2 - 9305702

AN - SCOPUS:0030772116

VL - 80

SP - 1029

EP - 1033

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 6

ER -